Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study.
Adjuvant therapy
Breast cancer survivorship
CIPN20
Chemotherapy
Chemotherapy-Induced Peripheral Neuropathy CIPN
Financial toxicity
Functional health
Health-related quality of life
QLQ-C30
Quality of life
Survivorship
Taxane
Taxane-induced peripheral neuropathy
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
28
03
2022
accepted:
02
07
2022
pubmed:
9
8
2022
medline:
14
9
2022
entrez:
8
8
2022
Statut:
ppublish
Résumé
We explored the impact of persistent sensory and motor taxane-induced peripheral neuropathy (TIPN) symptoms on health-related quality of life (HRQL) among early-stage breast cancer survivors (ESBCS). A population-based cohort of 884 residual-free ESBCS received a postal questionnaire, including the EORTC chemotherapy-induced PN (CIPN20) and the EORTC QLQ-C30 instruments. Mean scores of QLQ-C30 scales among ESBCS with and without TIPN were calculated and adjusted for confounding factors (age, lifestyle factors, co-morbidities; linear regression analyses). Interpretation of QLQ-C30 results were based on guidelines. Response rate was 79%, and 646 survivors were included in the analysis. In median, 3.6 (1.5-7.3) years had elapsed post-taxane treatment. All TIPN symptoms had a significant impact on global QoL, which worsened with increased severity of TIPN. Between 29.5% and 93.3% of ESBCS with moderate-severe TIPN reported a clinical important impairment of functioning and personal finances, 64.3-85.7% reporting "difficulty walking because of foot drop," and 53.1-81.3% reporting "problems standing/walking because of difficulty feeling ground under feet" had impaired functioning/finances. The difference in mean scores between affected and non-affected survivors was highest for "numbness in toes/feet" and "difficulty walking because of foot drop." Moderate-severe "difficulty climbing stairs or getting out of chair because of weakness of legs" and "problems standing/walking because of difficulty feeling ground under feet" were associated with the largest clinically important differences on all scales. Persistent sensory and motor TIPN is associated with clinically relevant impairment of global QoL, functioning, and personal finances among ESBCS, which increased with level of TIPN severity.
Sections du résumé
BACKGROUND
BACKGROUND
We explored the impact of persistent sensory and motor taxane-induced peripheral neuropathy (TIPN) symptoms on health-related quality of life (HRQL) among early-stage breast cancer survivors (ESBCS).
METHODS
METHODS
A population-based cohort of 884 residual-free ESBCS received a postal questionnaire, including the EORTC chemotherapy-induced PN (CIPN20) and the EORTC QLQ-C30 instruments. Mean scores of QLQ-C30 scales among ESBCS with and without TIPN were calculated and adjusted for confounding factors (age, lifestyle factors, co-morbidities; linear regression analyses). Interpretation of QLQ-C30 results were based on guidelines.
RESULTS
RESULTS
Response rate was 79%, and 646 survivors were included in the analysis. In median, 3.6 (1.5-7.3) years had elapsed post-taxane treatment. All TIPN symptoms had a significant impact on global QoL, which worsened with increased severity of TIPN. Between 29.5% and 93.3% of ESBCS with moderate-severe TIPN reported a clinical important impairment of functioning and personal finances, 64.3-85.7% reporting "difficulty walking because of foot drop," and 53.1-81.3% reporting "problems standing/walking because of difficulty feeling ground under feet" had impaired functioning/finances. The difference in mean scores between affected and non-affected survivors was highest for "numbness in toes/feet" and "difficulty walking because of foot drop." Moderate-severe "difficulty climbing stairs or getting out of chair because of weakness of legs" and "problems standing/walking because of difficulty feeling ground under feet" were associated with the largest clinically important differences on all scales.
CONCLUSION
CONCLUSIONS
Persistent sensory and motor TIPN is associated with clinically relevant impairment of global QoL, functioning, and personal finances among ESBCS, which increased with level of TIPN severity.
Identifiants
pubmed: 35941422
doi: 10.1007/s10549-022-06670-9
pii: 10.1007/s10549-022-06670-9
pmc: PMC9464756
doi:
Substances chimiques
Taxoids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
379-391Subventions
Organisme : Futurum - Akademin för Hälsa och Vård, Region Jönköpings läns
ID : 575361
Organisme : Forskningsrådet i Sydöstra Sverige
ID : 932359
Organisme : Cancerfonden
ID : 190224
Informations de copyright
© 2022. The Author(s).
Références
Br J Cancer. 2021 Aug;125(3):445-457
pubmed: 34017086
Lancet. 2012 Feb 4;379(9814):432-44
pubmed: 22152853
J Clin Oncol. 2011 Jan 1;29(1):89-96
pubmed: 21098316
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Qual Life Res. 2018 Aug;27(8):2077-2086
pubmed: 29740782
J Natl Cancer Inst. 2018 Feb 1;110(2):
pubmed: 28954297
Breast. 2021 Oct;59:110-116
pubmed: 34225091
Breast Cancer Res Treat. 2022 Apr;192(2):293-301
pubmed: 34982322
J Clin Epidemiol. 2020 Feb;118:1-8
pubmed: 31639445
J Clin Oncol. 1993 Mar;11(3):570-9
pubmed: 8445433
J Cancer Surviv. 2021 Mar 12;:
pubmed: 33710510
Med Care. 2003 May;41(5):582-92
pubmed: 12719681
JAMA. 2013 Apr 3;309(13):1359-67
pubmed: 23549581
J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735
J Natl Cancer Inst. 2018 Feb 1;110(2):
pubmed: 28954296
Cochrane Database Syst Rev. 2019 Sep 02;9:CD004421
pubmed: 31476253
Arch Intern Med. 1998 Sep 14;158(16):1789-95
pubmed: 9738608
J Clin Oncol. 2020 Oct 1;38(28):3325-3348
pubmed: 32663120
Eur J Cancer. 2015 Feb;51(3):292-300
pubmed: 25541155
J Clin Oncol. 2014 Jun 20;32(18):1941-67
pubmed: 24733808
Ann Oncol. 2020 Oct;31(10):1306-1319
pubmed: 32739407
Ann Oncol. 2009 Aug;20(8):1319-29
pubmed: 19535820
Scand J Public Health. 2016 Feb;44(1):70-6
pubmed: 26392418